Uppsala, Sweden, 2011-08-31 11:00 CEST (GLOBE NEWSWIRE) -- Ahead of the Annual General Meeting in Oasmia Pharmaceutical AB (“Oasmia”) on September 30, 2011 the Nomination Committee, constituted by Björn Björnsson (Chairman of the Board), Julian Aleksov (represents Oasmia’s largest shareholder Alceco International S.A.) and Johan Edin (independent of the largest shareholders and the Company Management and Board of Directors), proposes the election of six Board members and no Deputy members.
The Nomination Committee proposes the re-election of Bo Cederstrand and Julian Aleksov. In order to expand the Board’s international experience and competences regarding the pharmaceutical industry and financial markets the Nomination Committee proposes Joel Citron, Martin Nicklasson, Jan Lundberg and Prof. Dr. Horst Domdey to be elected Board members. The Nomination Committee proposes that Joel Citron is elected Chairman of the Board. Björn Björnsson, Peter Ström and Claes Piehl have declined re-election.
Joel Citron has a long experience from leading positions within both private and listed companies as well as from being a professional investor. Mr. Citron is currently the Managing Director and CEO of New York-based Tenth Avenue Holdings, investing in private and listed companies, and in real estate. From 2002 to 2008, Mr. Citron served as President and CEO of Jovian Holdings, a privately held investment and operating company. From 1998 to 2001, Mr. Citron was Director, Deputy Chairman, President and CEO of Mastec Inc., a leading NYSE traded end-to-end communications and energy infrastructure service provider. Prior to 2001, Mr. Citron spent 16 years in various leadership positions in investment and operating companies. Mr. Citron has been the Chairman and a Director of several public and private companies in Europe and the United States. From 2001 to 2006, he served as Chairman of the Board of Directors of Provide Commerce Inc., a publicly traded e-commerce company and from 2002 to 2009 he served as Chairman of the Board of Oxigene Inc., a publicly traded biotech company. Mr. Citron currently serves as Chairman of the Board of Avenue Income Credit Strategies Fund, a publicly traded mutual fund and as Chairman and/or Director of several privately held companies. In addition to his corporate engagements, Mr. Citron is actively involved in non-profit institutions and with several educational organizations. Mr. Citron holds an MA in Economics and a BSc in Business Administration from the University of Southern California.
Martin Nicklasson has a long experience from the pharmaceutical industry. Mr. Nicklasson was most recently the CEO of Swedish Orphan International during 2007–2010. Prior to that, he has a long withstanding career within AstraZeneca during 1978–1989 and 1991–2007. Most recently Mr. Nicklasson was responsible for Global Marketing and Business Development within AstraZeneca and CEO of AstraZeneca Sweden AB. In 1996 he was appointed responsible for Astra Hässle. Under Mr. Nicklasson’s direction NEXIUM, that currently sells for more than USD 5 billion per year, was developed and launched. During 1989–1991 Mr. Nicklasson was responsible for Research and Development within KABI. Mr. Nicklasson is a certified Pharmacist and holds, since 1982, a PhD in Pharmaceutical Technology at the University of Uppsala. Since 1985, Mr. Nicklasson is an Associate Professor at the Pharmaceutical Faculty at Uppsala University.
Jan Lundberg has a long experience from business activities. Today’s operations are carried out form the wholly owned company Rekonstructa AB and includes property ownership and property management, trading in stocks, joint ownership in companies as well as a number of mandates from external customers. Since 1985, Mr. Lundberg has operated through his own company. During 1972–1985 Mr. Lundberg was employed with Salén & Wicander AB. He became the CEO in 1977 and a lot of focus was aimed at intensifying the marketing of Salén & Wicander’s own products to customers such as ship owners, ship yards and ports. Mr. Lundberg holds a MSc degree in Mechanical Engineering, and Industrial Engineering and Management from the Royal Institute of Technology in Stockholm.
Prof. Dr. Horst Domdey has a long experience in biochemistry and molecular biology. He is currently the Managing Director and CEO of Bio-M AG and Bio-M GmbH, and Chairman of the Munich Biotech Cluster. He has been the co-founder of MediGene AG and Switch Biotech AG. Dr. Domdey has previously held several positions in, among others, the Max Planck Institute of Biochemistry, the Swiss Institute for Experimental Cancer Research (ISREC), the University of California and the California Institute of Technology. In addition, he held the position as Associate Professor in Biochemistry at the Ludwig Maximilian University Munich.
The Nomination Committee proposes Mikael Smedeby as Chairman of the Annual General Meeting.
Remuneration to Board members that are not employed with the company shall be paid an amount of SEK 250,000 per year. The Nomination Committee proposes, in accordance with previous arrangements, that a new Nomination Committee shall be engaged at the latest six months before the Annual General Meeting in 2012 in accordance with the following principles:
- One member shall represent the largest shareholders
- One member shall be independent of the largest shareholders as well as the Management and Board of Directors
- One member shall be the Chairman of the Board
The term of the Nomination Committee shall last until a new Nomination Committee has been appointed. If a member leaves the Nomination Committee before the termination of the assignment the other members shall appoint an alternate member.
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB.E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. German contacts: Dr. Sönke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt, Germany. E-Mail: oasmia@edicto.de, Phone: +49 (0) 69 90 55 05 51. Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de
